Why 75% of Alzheimer’s Patients Are Women: The Gut-Hormone Connection

About 75% of Alzheimer's patients are female, and researchers have long struggled to explain why the gap is so wide. A review published in Seminars in Immunopathology by Aisa Bahar, Meisam Khazaei, and Hamed Tahmasebi proposes that the answer may lie, at least in part, in the gut. Their analysis maps a three-way interplay among gut microbiota, microbial metabolites, and sex hormones that could be shaping who gets Alzheimer's disease, how fast it progresses, and why women bear a disproportionate burden.

Gut dysbiosis, metabolites, and Alzheimer's pathology

Disruption of the normal gut microbial community, called gut dysbiosis, is now considered a clear risk factor for Alzheimer's disease. When the microbial balance tips, the consequences reach far beyond the intestine. Dysbiosis triggers immune system activation, degrades the lining of both the gut and the blood-brain barrier, and alters the chemical signals that travel along the microbiota-gut-brain axis. The result, according to the review, is a permissive environment for neuroinflammation and the buildup of amyloid plaques and tau tangles.

The specific molecules carrying these signals matter enormously. Microbial metabolites serve as a molecular interface linking gut bacteria to brain function, and several classes are implicated in Alzheimer's pathology. Short-chain fatty acids (SCFAs), produced when gut bacteria ferment dietary fiber, play a complicated double role: depending on context, they can either dampen neuroinflammation or amplify it. Tryptophan and its breakdown products, including kynurenine, serotonin, and various indoles, carry neuroactive properties that influence mood, cognition, and immune tone. Bile acids recirculated by gut bacteria add another layer of modulation. Then there is trimethylamine N-oxide, or TMAO, a metabolite the review flags as particularly worrying: elevated TMAO is associated with dyslipidemia, endothelial dysfunction, systemic inflammation, and accelerated metabolic decline, all of which have been independently linked to Alzheimer's risk.

Why women shoulder more of the Alzheimer's burden

Genetics, brain structure, and lifestyle factors all contribute to the female skew in Alzheimer's prevalence, but the review highlights one underappreciated angle: estrogen's complicated relationship with neuroinflammation. Estrogen appears to suppress the activity of microglia, the brain's resident immune cells. That sounds protective at first glance, but the authors suggest it may actually allow amyloid plaques to accumulate more freely in female brains, because an underactive microglial response clears less of the pathological protein. Research at the University of Chicago has similarly found that estrogen influences amyloid plaque formation and inflammation through gut-mediated pathways, pointing toward the microbiome as a key intermediary.

Animal data sharpens the picture. Studies in female Alzheimer's model mice have shown that gut dysbiosis alters estradiol levels, disrupts the estrous cycle, and impairs cognition, suggesting the gut-hormone feedback loop is not merely correlational. Bahar and colleagues extend this logic to human sex-specific pathophysiology, framing the gut microbiome as a modulator of vulnerability rather than a passive bystander.

The estrobolome, testobolome, and the microgenderome

The review introduces three terms worth understanding. The "estrobolome" refers to the subset of gut microbial genes capable of metabolizing estrogens, effectively giving bacteria a hand in regulating circulating estrogen levels. A disrupted estrobolome means estrogen is either over- or under-recycled, with downstream effects on brain inflammation and cognitive aging. The authors also propose the concept of a "testobolome" to describe an analogous microbial role in testosterone metabolism, though this framework is newer and less supported by data.

Tying both ideas together is the "microgenderome," a term for the bidirectional relationship between sex hormones and gut microbial composition. This goes both ways: hormones shape which bacteria thrive, and bacteria shape how hormones circulate. Genetic predisposition, hormonal shifts across the lifespan, and gut microbiome perturbations interact to create sex-specific susceptibility patterns in Alzheimer's disease, particularly around menopause when estrogen levels fall sharply. The microgenderome concept, while still emerging, offers a biological framework for why the same pathological processes might unfold differently in men and women.

Open questions about causality and clinical translation

The review synthesizes a compelling body of evidence, but the authors are careful not to overstate it. Most mechanistic data comes from animal models or observational studies in humans, and establishing clean causal chains from gut bacteria through metabolites to Alzheimer's pathology in people remains difficult. Which microbial imbalances drive disease versus which are a consequence of it is still unclear. The precise mechanisms of microbial interventions and how to tailor them to individual metabolic profiles remain unknown, a gap that complicates any move toward clinical application.

Sex is also treated as a binary throughout the review, which limits the generalizability of the microgenderome framework. Hormonal variation across the menstrual cycle, during pregnancy, and after surgical menopause adds complexity that a review-level synthesis can only gesture toward. The relative contributions of specific SCFA species, bile acid subtypes, and tryptophan metabolites to Alzheimer's onset versus progression also remain to be disentangled.

Probiotics, fecal transplants, and diet as possible routes forward

Despite those caveats, the review ends on a constructive note. Because the gut microbiome is, in principle, modifiable, it represents a therapeutic target that purely neurological approaches to Alzheimer's do not offer. The authors discuss several strategies: dietary interventions to shift microbial composition, probiotics to restore beneficial bacterial populations, fecal microbiota transplantation to more wholesale reset dysbiosis, and compounds from traditional Chinese medicine with documented effects on gut flora. Promising interventions including anti-inflammatory diets and fecal microbiota transplantation have shown potential for restoring microbial balance and improving cognitive outcomes, though most trials are small and short-term.

The National Institute on Aging is actively funding research into whether harmful changes in the gut-brain axis can be reversed to prevent or slow Alzheimer's, a sign that the field is moving toward intervention studies rather than just mechanistic mapping. For now, the review's most concrete contribution is a detailed blueprint of how gut bacteria, the metabolites they produce, and the sex hormones they help regulate may conspire to determine who develops Alzheimer's disease and how severely. That blueprint, if it holds up, could eventually point toward a generation of treatments calibrated not just to plaques and tangles, but to the microbial ecosystem sustaining the brain.

Evidence rating

EMERGING — 75/100

Caveats:

• This is a narrative review synthesizing existing studies, not an original clinical trial — it cannot establish causation.
• No funding source is disclosed for this review.
• Many of the proposed mechanisms (e.g., the 'testobolome') are conceptual and have not yet been tested in independent human studies.
• Findings should be considered hypothesis-generating until confirmed by prospective trials.

Narrative review synthesizing mechanistic and epidemiological literature on gut microbiota, sex hormones, and Alzheimer's disease. Proposes step-by-step pathways but generates no new primary data and cannot establish causation. Core metabolite mechanisms draw on a growing body of prior work, though the 'testobolome' concept and several sex-specific claims await independent prospective validation.